Barclays
FLGT icon

Barclays’s Fulgent Genetics FLGT Stock Holding History

Barclays’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$970K Buy
44,045
+11,699
+36% +$235K ﹤0.01% 3071
2026
Q2 		$664K Sell
32,346
-108,665
-77% -$1.84M ﹤0.01% 3050
2026
Q1 		$2.24M Sell
141,011
-31,275
-18% -$679K ﹤0.01% 2290
2025
Q4 		$4.53M Sell
172,286
-6,581
-4% -$171K ﹤0.01% 2297
2025
Q3 		$4.04M Sell
178,867
-18,712
-9% -$385K ﹤0.01% 2359
2025
Q2 		$3.93M Buy
197,579
+5,581
+3% +$109K ﹤0.01% 2324
2025
Q1 		$3.24M Buy
191,998
+11,601
+6% +$198K ﹤0.01% 2266
2024
Q4 		$3.33M Buy
180,397
+5,542
+3% +$108K ﹤0.01% 2502
2024
Q3 		$3.8M Buy
174,855
+32,250
+23% +$721K ﹤0.01% 2310
2024
Q2 		$2.8M Sell
142,605
-8,536
-6% -$178K ﹤0.01% 1899
2024
Q1 		$3.28M Buy
151,141
+101,607
+205% +$2.52M ﹤0.01% 2156
2023
Q4 		$1.43M Buy
49,534
+35,904
+263% +$961K ﹤0.01% 3175
2023
Q3 		$364K Buy
13,630
+910
+7% +$31.1K ﹤0.01% 2979
2023
Q2 		$471K Sell
12,720
-907
-7% -$31.6K ﹤0.01% 2789
2023
Q1 		$425K Buy
13,627
+3,765
+38% +$121K ﹤0.01% 3377
2022
Q4 		$294K Buy
9,862
+4,552
+86% +$163K ﹤0.01% 3636
2022
Q3 		$203K Sell
5,310
-5,475
-51% -$274K ﹤0.01% 3197
2022
Q2 		$589K Sell
10,785
-9,253
-46% -$509K ﹤0.01% 2752
2022
Q1 		$1.25M Sell
20,038
-8,642
-30% -$569K ﹤0.01% 2227
2021
Q4 		$2.88M Buy
28,680
+8,393
+41% +$738K ﹤0.01% 2124
2021
Q3 		$1.82M Buy
20,287
+7,924
+64% +$720K ﹤0.01% 2416
2021
Q2 		$1.14M Sell
12,363
-6,216
-33% -$496K ﹤0.01% 2573
2021
Q1 		$1.79M Buy
18,579
+3,910
+27% +$404K ﹤0.01% 2377
2020
Q4 		$764K Buy
14,669
+1,204
+9% +$50.3K ﹤0.01% 2951
2020
Q3 		$540K Buy
13,465
+8,116
+152% +$254K ﹤0.01% 3178
2020
Q2 		$85K Buy
+5,349
New +$81.9K ﹤0.01% 4621
2017
Q3 		– Sell
-4,800
Closed -$31K – 6903
2017
Q2 		$31K Buy
4,800
+3,778
+370% +$30.5K ﹤0.01% 5591
2017
Q1 		$11K Buy
1,022
+920
+902% +$10.9K ﹤0.01% 6041
2016
Q4 		$1K Buy
+102
New +$963 ﹤0.01% 6453

Other funds holding FLGT

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Barclays's FLGT Position: Q3 2026 in Review

Barclays increased its Fulgent Genetics (FLGT) stake by 36% in Q3 2026, buying an estimated $235K and bringing the position to 44,045 shares worth $970K. The position accounts for ﹤0.01% of the portfolio, ranked #3071.

Barclays first reported a position in FLGT in Q4 2016 and has held it in 29 quarters since. The position peaked at $4.53M in Q4 2025. 47 funds tracked by Wall St. Rank hold FLGT as of Q3 2026.

  • Barclays held 44,045 shares of Fulgent Genetics worth $970K as of Q3 2026.
  • Barclays bought 11,699 Fulgent Genetics shares in Q3 2026, an estimated $235K.
  • Fulgent Genetics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3071 holding.
  • Barclays first reported a position in Fulgent Genetics in Q4 2016 and has held it in 29 quarters since.
  • Barclays's Fulgent Genetics position peaked at $4.53M in Q4 2025.
  • 47 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.